Jurkus Regimantas, Day Harriet L L, Guimarães Francisco S, Lee Jonathan L C, Bertoglio Leandro J, Stevenson Carl W
School of Mathematical Sciences, University of Nottingham University Park, Nottingham, UK.
School of Biosciences, University of Nottingham Loughborough, UK.
Front Pharmacol. 2016 Nov 24;7:454. doi: 10.3389/fphar.2016.00454. eCollection 2016.
Anxiety and trauma-related disorders are psychiatric diseases with a lifetime prevalence of up to 25%. Phobias and post-traumatic stress disorder (PTSD) are characterized by abnormal and persistent memories of fear-related contexts and cues. The effects of psychological treatments such as exposure therapy are often only temporary and medications can be ineffective and have adverse side effects. Growing evidence from human and animal studies indicates that cannabidiol, the main non-psychotomimetic phytocannabinoid present in , alleviates anxiety in paradigms assessing innate fear. More recently, the effects of cannabidiol on learned fear have been investigated in preclinical studies with translational relevance for phobias and PTSD. Here we review the findings from these studies, with an emphasis on cannabidiol regulation of contextual fear. The evidence indicates that cannabidiol reduces learned fear in different ways: (1) cannabidiol decreases fear expression acutely, (2) cannabidiol disrupts memory reconsolidation, leading to sustained fear attenuation upon memory retrieval, and (3) cannabidiol enhances extinction, the psychological process by which exposure therapy inhibits learned fear. We also present novel data on cannabidiol regulation of learned fear related to explicit cues, which indicates that auditory fear expression is also reduced acutely by cannabidiol. We conclude by outlining future directions for research to elucidate the neural circuit, psychological, cellular, and molecular mechanisms underlying the regulation of fear memory processing by cannabidiol. This line of investigation may lead to the development of cannabidiol as a novel therapeutic approach for treating anxiety and trauma-related disorders such as phobias and PTSD in the future.
焦虑和创伤相关障碍是终生患病率高达25%的精神疾病。恐惧症和创伤后应激障碍(PTSD)的特征是对恐惧相关情境和线索存在异常且持续的记忆。暴露疗法等心理治疗的效果往往只是暂时的,而药物治疗可能无效且有不良副作用。来自人类和动物研究的越来越多的证据表明,大麻二酚(CBD),即大麻中主要的非致幻性植物大麻素,在评估先天恐惧的范式中可减轻焦虑。最近,在与恐惧症和PTSD具有转化相关性的临床前研究中,对大麻二酚对习得性恐惧的影响进行了调查。在此,我们回顾这些研究的结果,重点关注大麻二酚对情境性恐惧的调节作用。证据表明,大麻二酚以不同方式减少习得性恐惧:(1)大麻二酚可急性降低恐惧表达;(2)大麻二酚破坏记忆巩固,导致记忆提取时恐惧持续减轻;(3)大麻二酚增强消退作用,即暴露疗法抑制习得性恐惧的心理过程。我们还展示了关于大麻二酚对与明确线索相关的习得性恐惧调节的新数据,这表明大麻二酚也可急性降低听觉恐惧表达。我们通过概述未来研究方向来得出结论,以阐明大麻二酚调节恐惧记忆处理的神经回路、心理、细胞和分子机制。这一系列研究可能会促使未来将大麻二酚开发为治疗焦虑和创伤相关障碍(如恐惧症和PTSD)的新型治疗方法。